Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARQ 234

Next Previous
X
Search
Drug Profile

ARQ 234

Alternative Names: ARQ-234; DS-234

Latest Information Update: 21 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ducentis BioTherapeutics
  • Class Anti-inflammatories; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action CD200R1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 14 Aug 2024 Arcutis Biotherapeutics plans to file an IND application for Atopic dermatitis in 2025
  • 17 Mar 2023 Arcutis Biotherapeutics has patents pending for ARQ 234 and other CD200 mutant proteins in Brazil, Canada, Europe, Hong Kong, India, Korea, New Zealand, Singapore
  • 31 Dec 2022 Arcutis Biotherapeutics has patent protection for ARQ 234 and other CD200 mutant protein in USA, Australia, China, Eurasia, Israel, Japan, Mexico, South Korea and South Africa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top